SAN DIEGO, CA, Apr. 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnologycompany pioneering molecular glue degraders to address previously undruggable proteins,today announced the closing of a $100 million Series B financing. The round was led byDeerfield Management with participation from new investors Regeneron Ventures, LongwoodFund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute,and others.
“This financing is a testament to the science, strategy, and team we have built at Neomorph,and it provides us with the capital to execute on our most important near-term priorities,” saidPhil Chamberlain, D.Phil., Co-Founder, President, and Chief Executive Officer of Neomorph.“We remain focused on executing the Phase 1/2 trial of NEO-811 to generate clinical data thatwill inform continued development, while advancing a broader pipeline of novel molecular gluedegraders against targets that have historically been considered undruggable. We are delightedto welcome new partners and grateful for the continued support of our founding investor,Deerfield. We look forward to working together to deliver innovative medicines for patients withsignificant unmet need.”
Proceeds from the financing will primarily support the advancement of the ongoing NEO-811Phase 1/2 trial, a first-in-human, open-label monotherapy study evaluating the safety, tolerability,pharmacokinetics, and preliminary anti-tumor activity in patients with locally advanced ormetastatic non-resectable clear cell renal cell carcinoma (ccRCC). The capital will also supportadvancement of Neomorph’s pipeline across multiple therapeutic areas, driven by its proprietaryplatform to unlock targets that have historically been unreachable with conventional drugdiscovery.
“We believe that Neomorph has built a differentiated platform with the scientific depth tosystematically access a vast new target space, as well as a team with the expertise to translatekey findings into compelling drug candidates,” said Cam Wheeler, Ph.D., Partner at DeerfieldManagement and Chair of Neomorph’s board of directors. “Additionally, the confidence ofleading global pharmaceutical companies, including Novo Nordisk, Biogen, and AbbVie, whohave partnered with Neomorph across cardiometabolic disease, rare disease, neurology,oncology, and immunology, speaks to the versatility of this platform and provides multiplepotential paths to validation. We are proud to continue supporting Neomorph as the companyadvances its molecular glue technology through clinical trials and works to redefine the universeof therapeutic targets available to physicians and patients.”
About NEO-811
NEO-811 is an investigational molecular glue degrader designed to induce targeted degradationof a protein called ARNT, also known as HIF-1β, and fully block a central signaling pathwayimplicated in ccRCC. By leveraging a differentiated degradation mechanism, NEO-811 has thepotential to address underlying tumor biology that remains inadequately treated with currentstandards of care. NEO-811 is currently being evaluated as a monotherapy in a first-in-humanPhase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable ccRCC.
About Neomorph
Neomorph is a biotechnology company pioneering the discovery and development of molecularglue degraders to unlock new therapeutic possibilities across serious diseases. By engineeringneomorphic protein surfaces, Neomorph enables precisely targeted protein degradation ofdisease drivers that have historically been considered undruggable. As a leader in molecularglue technology, Neomorph has created the world’s largest proprietary molecular glue targetspace, spanning multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases.The company was founded in 2020.